google-site-verification: googlec7193c3de77668c9.html

Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation

[
Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).


Source link

Advertisements

See also  Unfavorable social factors may raise heart disease risk factors in Asian American adults

Check Also

The fight to say 'vagina' on social media

The fight to say ‘vagina’ on social media BBC News Khamrah by Lattafa for Men …

AI detects coronary heart disease from face and tongue photos in small test

[ An AI system trained on photographs of the face and tongue correctly identified every …

Russian man linked to deadly London hospitals hack arrested

German police have detained a Russian man accused of being part of a cyber-crime gang …

Leave a Reply

Available for Amazon Prime